Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and chloramphenicol

sorafenib has been researched along with chloramphenicol in 3 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(chloramphenicol)		Trials
(chloramphenicol)		Recent Studies (post-2010) (chloramphenicol)
6,5207305,25120,1133881,464

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)chloramphenicol (IC50)
30S ribosomal protein S6Escherichia coli K-120.43
30S ribosomal protein S7Escherichia coli K-120.43
50S ribosomal protein L15Escherichia coli K-120.43
50S ribosomal protein L10Escherichia coli K-120.43
50S ribosomal protein L11Escherichia coli K-120.43
50S ribosomal protein L7/L12Escherichia coli K-120.43
50S ribosomal protein L19Escherichia coli K-120.43
50S ribosomal protein L1Escherichia coli K-120.43
50S ribosomal protein L20Escherichia coli K-120.43
50S ribosomal protein L27Escherichia coli K-120.43
50S ribosomal protein L28Escherichia coli K-120.43
50S ribosomal protein L29Escherichia coli K-120.43
50S ribosomal protein L31Escherichia coli K-120.43
50S ribosomal protein L31 type BEscherichia coli K-120.43
50S ribosomal protein L32Escherichia coli K-120.43
50S ribosomal protein L33Escherichia coli K-120.43
50S ribosomal protein L34Escherichia coli K-120.43
50S ribosomal protein L35Escherichia coli K-120.43
50S ribosomal protein L36Escherichia coli K-120.43
30S ribosomal protein S10Escherichia coli K-120.43
30S ribosomal protein S11Escherichia coli K-120.43
30S ribosomal protein S12Escherichia coli K-120.43
30S ribosomal protein S13Escherichia coli K-120.43
30S ribosomal protein S16Escherichia coli K-120.43
30S ribosomal protein S18Escherichia coli K-120.43
30S ribosomal protein S19Escherichia coli K-120.43
30S ribosomal protein S20Escherichia coli K-120.43
30S ribosomal protein S2Escherichia coli K-120.43
30S ribosomal protein S3Escherichia coli K-120.43
30S ribosomal protein S4Escherichia coli K-120.43
30S ribosomal protein S5Escherichia coli K-120.43
30S ribosomal protein S8Escherichia coli K-120.43
30S ribosomal protein S9Escherichia coli K-120.43
50S ribosomal protein L13Escherichia coli K-120.43
50S ribosomal protein L14Escherichia coli K-120.43
50S ribosomal protein L16Escherichia coli K-120.43
50S ribosomal protein L23Escherichia coli K-120.43
30S ribosomal protein S15Escherichia coli K-120.43
50S ribosomal protein L17Escherichia coli K-120.43
50S ribosomal protein L21Escherichia coli K-120.43
50S ribosomal protein L30Escherichia coli K-120.43
50S ribosomal protein L6Escherichia coli K-120.43
30S ribosomal protein S14Escherichia coli K-120.43
30S ribosomal protein S17Escherichia coli K-120.43
30S ribosomal protein S1Escherichia coli K-120.43
50S ribosomal protein L18Escherichia coli K-120.43
50S ribosomal protein L2Escherichia coli K-120.43
50S ribosomal protein L3Escherichia coli K-120.43
50S ribosomal protein L24Escherichia coli K-120.43
50S ribosomal protein L4Escherichia coli K-120.43
50S ribosomal protein L22Escherichia coli K-120.43
50S ribosomal protein L5Escherichia coli K-120.43
30S ribosomal protein S21Escherichia coli K-120.43
50S ribosomal protein L25Escherichia coli K-120.43
50S ribosomal protein L36 2Escherichia coli K-120.43

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for sorafenib and chloramphenicol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for sorafenib and chloramphenicol

ArticleYear
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012